263 related articles for article (PubMed ID: 33249625)
1. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients.
Hafezi M; Lin M; Chia A; Chua A; Ho ZZ; Fam R; Tan D; Aw J; Pavesi A; Krishnamoorthy TL; Chow WC; Chen W; Zhang Q; Wai LE; Koh S; Tan AT; Bertoletti A
Hepatology; 2021 Jul; 74(1):200-213. PubMed ID: 33249625
[TBL] [Abstract][Full Text] [Related]
2. Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer.
Hafezi M; Tan A; Bertoletti A
Cells; 2021 Jul; 10(8):. PubMed ID: 34440630
[TBL] [Abstract][Full Text] [Related]
3. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
4. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract][Full Text] [Related]
5. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
6. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.
Kah J; Koh S; Volz T; Ceccarello E; Allweiss L; Lütgehetmann M; Bertoletti A; Dandri M
J Clin Invest; 2017 Aug; 127(8):3177-3188. PubMed ID: 28737510
[TBL] [Abstract][Full Text] [Related]
7. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood.
Lin M; Bhakdi SC; Tan D; Lee JJX; Tai DWM; Pavesi A; Wai LE; Wang T; Bertoletti A; Tan AT
Immunother Adv; 2023; 3(1):ltad015. PubMed ID: 37636242
[TBL] [Abstract][Full Text] [Related]
8. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
Lee SWL; Adriani G; Ceccarello E; Pavesi A; Tan AT; Bertoletti A; Kamm RD; Wong SC
Front Immunol; 2018; 9():416. PubMed ID: 29559973
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital.
San Miguel C; Fundora Y; Triguero J; Muffak K; Villegas T; Becerra A; Garrote D; Ferrón JA
Transplant Proc; 2015 Oct; 47(8):2371-3. PubMed ID: 26518930
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F; Zhao J; Tan AT; Hu W; Wang SY; Jin J; Wu J; Li Y; Shi L; Fu JL; Yu S; Shen Y; Liu L; Luan J; Shi M; Xie Y; Zhou CB; Wong RW; Lu-En W; Koh S; Bertoletti A; Wang T; Zhang JY; Wang FS
Hepatol Int; 2021 Dec; 15(6):1402-1412. PubMed ID: 34850325
[TBL] [Abstract][Full Text] [Related]
13. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
Gehring AJ; Xue SA; Ho ZZ; Teoh D; Ruedl C; Chia A; Koh S; Lim SG; Maini MK; Stauss H; Bertoletti A
J Hepatol; 2011 Jul; 55(1):103-10. PubMed ID: 21145860
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria.
Vatansever S; Farajov R; Yılmaz HC; Zeytunlu M; Paköz ZB; Kılıç M
Turk J Gastroenterol; 2019 Jan; 30(1):75-80. PubMed ID: 30644364
[TBL] [Abstract][Full Text] [Related]
15. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT; Meng F; Jin J; Zhang JY; Wang SY; Shi L; Shi M; Li Y; Xie Y; Liu LM; Zhou CB; Chua A; Ho ZZ; Luan J; Zhao J; Li J; Wai LE; Koh S; Wang T; Bertoletti A; Wang FS
Hepatol Commun; 2022 Apr; 6(4):841-854. PubMed ID: 34935312
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center.
Hu AB; Wu LW; Tai Q; Zhu XF; He XS
J Dig Dis; 2013 Jan; 14(1):38-44. PubMed ID: 23134408
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
Qasim W; Brunetto M; Gehring AJ; Xue SA; Schurich A; Khakpoor A; Zhan H; Ciccorossi P; Gilmour K; Cavallone D; Moriconi F; Farzhenah F; Mazzoni A; Chan L; Morris E; Thrasher A; Maini MK; Bonino F; Stauss H; Bertoletti A
J Hepatol; 2015 Feb; 62(2):486-91. PubMed ID: 25308176
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
[TBL] [Abstract][Full Text] [Related]
19. Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients.
Uemoto S; Ozawa K; Kaido T; Mori A; Fujimoto Y
Clin Exp Immunol; 2016 Apr; 184(1):126-36. PubMed ID: 26560892
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
